Is LQDA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Yutrepia commercial ramp, with q1 2026 revenue at ~$133M (Yutrepia net sales ~$130M). The bear case rests on liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. Analysts covering it are spread from $60.00 to $130.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $60.00, -29.6% from the $85.22 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Yutrepia commercial ramp. Yutrepia posted about $130 million in first-quarter 2026 net sales, up sharply sequentially, and the company reported more than 4,500 unique prescriptions and roughly 3,750 patients treated since the June 2025 launch. The most optimistic analyst target on LQDA is $130.00, +52.5% from the $85.22 price. That figure is only reachable if this thesis works close to its best case.

Liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. United Therapeutics has an ongoing patent-infringement lawsuit (centered on U.S. Patent No. 11,826,327, which expires in 2042) that went to trial in June 2025 with a decision awaited, and an adverse ruling in that or related patent matters could limit Liquidia's ability to keep approval for or commercialize Yutrepia. The company competes directly against United Therapeutics' larger, entrenched Tyvaso franchise. The stock also carries a premium valuation that assumes continued rapid growth toward the stated $1 billion 2027 target, so any disappointment on volumes, pricing, or litigation could produce sharp downside, and L606 approval is not guaranteed. The most pessimistic published target is $60.00, -29.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Liquidia Corporation is a specialty pharmaceutical company focused on treating pulmonary hypertension.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Yutrepia commercial ramp) stalling in the reported numbers rather than in the narrative, the risk above (liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Liquidia is a specialty pharmaceutical company focused on pulmonary hypertension. Its lead product, Yutrepia, is an inhaled dry-powder form of treprostinil approved for pulmonary arterial hypertension and PH-ILD, and it is also developing L606, a longer-acting inhaled treprostinil candidate.

Yes, recently. Driven by Yutrepia's rapid launch, Liquidia reported net income of roughly $53 million and adjusted EBITDA near $71 million in the first quarter of 2026, its third consecutive profitable quarter, a notable shift for a company that was pre-revenue before the June 2025 launch.

Yutrepia is Liquidia's inhaled dry-powder treprostinil product for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. It received final FDA approval in May 2025, launched in June 2025, and generated about $130 million in net sales in the first quarter of 2026.